Life Sciences

In vitro diagnostics introduces new technologies, sequencing methods, novel software algorithms, and multi-omics approaches to realise the goal of personalized medicine. Next-generation diagnostics has been the backbone of COVID-19-related emergency diagnosis, with an estimated 25% to 30% of revenue during 2020 and early 2021 related to this testin...

08 Mar 2022  |  North America

Global Pharmaceuticals Outlook, 2022

The Digitalization of the Pharmaceuticals Value Chain is Opening up New Growth Opportunities for Stakeholders

Infographics

×

Key Issues Addressed

Frost & Sullivan offers an outlook for the global pharmaceuticals market for 2022-2026, including emerging trends and growth opportunities. Prioritizing booster doses over initial dose coverage is negatively impacting the global mitigation of the COVID-19 pandemic, which is resulting in severe implications on health and social and economic well-bei...

The United States spends more than $3 trillion—nearly 18% of GDP—on healthcare, a massive sector. Healthcare value chain participants face dynamic environments that several trends impact, including the rise in the aging population (16.9% in 2020); chronic disease burden; regulatory challenges; integration across the care continuum; migration to...

Healthcare is rapidly becoming patient-centric, focusing on outcomes and value. This offers clinical diagnostics players opportunities to advance their instrument, assay, and informatics capabilities to address unmet clinical needs and increase the precision diagnostics portfolio. Advances in next-generation sequencing-based companion diagnosti...

Frost & Sullivan provides comprehensive insights into the global biologics contract development and manufacturing organization (bio-CDMO) market, including emerging trends, growth opportunities, and profiles of leading bio-CDMOs and their business model evolution. The growth of next-generation biologics and personalized therapies and the emergence ...

The global pharmaceutical industry is witnessing dynamic trends following the coronavirus pandemic and is adapting to new challenges and opportunities. This study analyzes the 2021 highlights in the global pharmaceutical industry and provides forecasts for the next year and beyond. It addresses the impact of innovative modalities, technologies, ...

08 Oct 2021  |  North America

Global Tissue Diagnostics (TDx) Growth Opportunities

Companion Diagnostics (CDx)-specific Advanced Staining and Anatomical Pathology Laboratory Information Systems (APLIS) to Drive Ma

Infographics

×

This research service provides an overview of the global TDx market and a 4-year forecast of it from 2021 to 2025. The market will reach $8,848.6 million in 2025, growing at a compound annual growth rate (CAGR) of 8.9% from 2020 to 2025. The advanced staining and anatomical pathology laboratory information management systems (APLIS) segments will g...

The change in reimbursement for diagnostic testing, pressure from PAMA, regulatory trends in Europe, demand for large-scale testing, shift to precision diagnostics, emerging companies, and evolving business models demand assessing portfolio, evaluating competitor strategies, and exploring opportunities for business growth. The competitive nature of...

This study presents Frost & Sullivan’s overall market and segment-wise revenue forecasts of the global small molecule contract development and manufacturing organization (CDMO) industry. It highlights key growth opportunities for small molecule CDMOs based on the main evolution in their business models and strategic approaches as well as those of...